Navigation Links
Amgen Announces Webcast of 2010 Fourth Quarter and Full Year Financial Results
Date:1/24/2011

THOUSAND OAKS, Calif., Jan. 24, 2011 /PRNewswire/ -- Amgen (Nasdaq: AMGN) today announced that it plans to report its fourth quarter and full year financial results on Monday, Jan. 24, 2011 after the close of the financial markets. The announcement will be followed by a conference call with the investment community at 2:00 p.m. Pacific Time.  Participating in the call from Amgen will be Kevin Sharer, chairman and chief executive officer, and other members of Amgen's senior management team.

Live audio of the conference call will be simultaneously broadcast over the Internet and will be available to members of the news media, investors and the general public. The conference call, including the question and answer session, is expected to last approximately one hour.

The webcast of the conference, as with other selected presentations regarding developments in Amgen's business given by management at certain investor and medical conferences, can be found on Amgen's website, www.amgen.com, under Investors. Information regarding presentation times, webcast availability and webcast links are noted on Amgen's Investor Relations Events Calendar.  The webcast will be archived and available for replay 72 hours after the event.

About Amgen

Amgen discovers, develops, manufactures, and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe, effective medicines from lab to manufacturing plant to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, bone disease, and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing scie
'/>"/>

SOURCE Amgen
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Amgen to Acquire BioVex, a Privately Held Biotechnology Company Headquartered in Woburn, Mass
2. Amgen and Xencor Enter Option Deal to Co-Develop Xencors Novel Antibody for Autoimmune Diseases
3. Call for Applications: The Amgen Award for Science Teaching Excellence
4. Amgen Foundation Recognizes Outstanding Staff Volunteers and Contributes $55,000 to Their Favorite Local Nonprofits
5. Amgen to Provide Testimony at FDA Hearing on Biosimilars
6. Amgen Highlights Data to Be Presented at American Society for Bone and Mineral Research (ASBMR) Meeting
7. Amgens Roger M. Perlmutter, M.D., Ph.D., Named 2009 AAAS Fellow, Recognized for Discovery, Development of Novel Medicines
8. Array BioPharma and Amgen Partner in Type 2 Diabetes
9. Amgen to Present at Lazard Capital Healthcare Conference
10. Amgen Announces Webcast of 2009 Third Quarter Financial Results
11. Amgen to Present at the Bank of America Merrill Lynch Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Vermillion, Inc. (Nasdaq:   VRML), a ... today that investors including Oracle Investment Management, ... several Vermillion directors have agreed to purchase approximately ... stock and warrants to purchase unregistered shares of ... Under the terms of the private ...
(Date:12/24/2014)... Dec. 23, 2014 Sigma-Aldrich Corporation (NASDAQ: ... waiting period under the Hart-Scott-Rodino Antitrust Improvements Act ... on December 22, 2014, thereby completing the U.S. ... the acquisition of the Company by Merck KGaA, ... satisfies another condition to closing the transaction, which ...
(Date:12/24/2014)... NEW YORK , Dec. 23, 2014 /PRNewswire/ ... study of mazindol in children with attention deficit/hyperactivity disorder ... December 2014 . The paper, titled ... attention deficit/hyperactivity disorder" ( Konofal et al, ... eCollection 2014 ) shows that mazindol might be ...
(Date:12/22/2014)... ROCKVILLE, Md. , Dec. 22, 2014 ... MKT: SYN), a developer of pathogen-specific therapies ... focus on protecting the microbiome, today announced ... a Phase 1a clinical trial of SYN-004, ... the prevention of Clostridium difficile (C. ...
Breaking Biology Technology:Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 2Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 4Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 5Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 2Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 3Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 2Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5
... Direct, a wholly owned subsidiary of Medco Health Solutions, ... provider of guidance and decision support for genomic medicine, ... Atlantic Health of Morristown, New Jersey, Crittenton Hospital Medical ... Chicago, Illinois, have joined the Genomic Medicine Network to ...
... 31, 2011 Caliper Life Sciences, Inc. (Nasdaq: ... agreed to a long-term, exclusive arrangement under which Caliper will ... North America. With the LabChip DS, an ... analyze the concentration levels of up to 96 nucleic acid ...
... Plus is pleased to offer Clinical and Non-Clinical ... health care organizations for front line selection and ... increase patient satisfaction and employee engagement and reduce turnover ... diminished medical errors and infection rates, better team dynamics, ...
Cached Biology Technology:Four Community Hospitals Join DNA Direct's Genomic Medicine Network 2Four Community Hospitals Join DNA Direct's Genomic Medicine Network 3Caliper Life Sciences Launches Microfluidic LabChip® DS Platform for UV/VIS Spectral Analysis of Nucleic Acid and Protein Samples 2Caliper Life Sciences Launches Microfluidic LabChip® DS Platform for UV/VIS Spectral Analysis of Nucleic Acid and Protein Samples 3Talent Plus' Health Care Talent Online® Assessments 2Talent Plus' Health Care Talent Online® Assessments 3
(Date:12/19/2014)... Research and Markets ( http://www.researchandmarkets.com/research/86ncd6/micro_market ) ... Monitor: North America Perimeter Security Systems Market" report ... The North American perimeter security market ... from 2014 to 2019. Although the U.S. market holds ... is expected to grow at a higher ...
(Date:12/17/2014)... 15, 2014 Research and Markets ... the "Samsung Galaxy S5 - Home Button ... their offering. http://photos.prnewswire.com/prnh/20130307/600769 ... sensing technology than the iPhone 5S, Samsung introduces ... its product. The Galaxy S5 home ...
(Date:12/17/2014)... N.C. , Dec. 16, 2014 Valencell, ... licensed its PerformTek biometric technology to industry leaders such ... highly accurate, clinically validated, biometric wearable products. These products ... 6-9 in Las Vegas . ... technology is accurate, flexible and robust – with the ...
Breaking Biology News(10 mins):Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 2Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 3Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2
... shirts in the shirt drawer, the time-honored lessons of helping ... of the brain are used to encode such categories as ... learning take place? , New research from Harvard Medical School ... such memories are found. They report in the advanced online ...
... of fast, effective treatments for cancer and viruses. , ... Nature Biotechnology, scientists describe how they have manipulated a ... a potential therapeutic tool. , "The process, called RNA ... and viruses," said research leader and Director of the ...
... only one strain of an infectious disease can exist ... study in the August issue of The American Naturalist, ... a mathematical model to help explain multiple strains, showing ... found that the coexistence of multiple infectious disease strains ...
Cached Biology News:Everything in its place: Researchers identify brain cells used to categorize images 2Everything in its place: Researchers identify brain cells used to categorize images 3
... host strains are K-12 derivatives that have ... and glutathione reductase (gor) genes, which greatly ... Studies have shown that expression in Origami(DE3) ... another host even though overall expression levels ...
Recommend to use at 1000X dilutions for cell culture (e.g. Add 1 ul to 1 ml of culture medium.)...
... Kit, 1 kit. Convenient way ... Conjugations are carried out under mild ... Dyes are packaged in premeasured amounts ... Category: Blotting & Labeling & Detection, ...
Recombinant Human Erythropoietin (Tissue Culture Grade)...
Biology Products: